A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

NCT00139867 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

UCB Pharma